DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Wegovy (semaglutide) for chronic weight management. Covered with PA under Aetna.
Aetna (CVS Health subsidiary) covers GLP-1s through standard commercial formularies and Aetna Medicare Advantage. Weight-loss indication generally requires BMI documentation.
BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity. Documented prior diet and exercise attempt of 6 months.
Aetna does not require step therapy from Saxenda or phentermine in most plans.
NovoCare Direct: $499/mo cash-pay for self-funded patients.
Aetna PA approval rate for Wegovy hovers around 75% when BMI documentation is thorough. Renewal at 12 months requires ≥5% weight loss.
Editorial summary, not legal or medical advice. Insurance formularies change quarterly. Verify with your specific plan member services before relying on any single source. Copay ranges reflect typical commercial plans; your plan may differ.